Effectiveness of treating non-specific pruritus vulvae with topical steroids: A randomized controlled trial
|
|
- Valerie Ferguson
- 6 years ago
- Views:
Transcription
1 European Journal of General Practice. 2009; 15: 2933 ORIGINAL ARTICLE Effectiveness of treating non-specific pruritus vulvae with topical steroids: A randomized controlled trial ANTOINE L. M. LAGRO-JANSSEN & SYLVIA SLUIS Department of General Practice, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands Downloaded By: [Radboud Universiteit Nijmegen] At: 07:15 22 March 2010 Abstract Objective: To determine the effectiveness of triamcinolone cream in the treatment of non-specific pruritus vulvae. Methods: A total of 50 patients, aged between 8 and 55 years, with non-specific pruritus vulvae were consecutively included in a doubleblind randomized controlled trial by their general practitioner in 25 general practices in the Netherlands. Analysis was by intention to treat. An infectious cause was excluded by a vaginal and cervical swab. After randomization, 27 patients were treated with triamcinolone cream and 23 patients with a placebo cream. The effectiveness was assessed by: change in the severity of itch visual analogue scale (VAS) score; the percentage of patients with complete recovery; and changes in general health according to COOP/WONCA charts. Results: The mean decrease in severity of itch was 2.08 points in the triamcinolone group compared to 3.26 points in the placebo group. Forty-two per cent of the women in the triamcinolone group completely recovered versus 35% in the placebo group. There was no difference in general health perception between the two groups. After 12 weeks, more than 80% in both groups reported recurrent vulval itch. Conclusion: No significant differences in effectiveness were found between the two groups, because both treatments were ineffective. We can conclude that triamcinolone cream is therefore not the treatment of first choice for non-specific pruritus vulvae. Key words: Pruritus vulvae, vulval disease, topical steroids, general practice, RCT Introduction Pruritus vulvae is an annoying and shameful problem in women. A study in the United Kingdom reported that general practitioners (GPs) saw more than one patient a month with vulval symptoms (1). It is known that recurrent vulval complaints may affect the psychological and sexual wellbeing of women. They report higher scores on depression scales and experience more psychological distress and reduced sexual satisfaction (2). Pruritus vulvae is the most common symptom among vulvar complaints. The aetiology of pruritus vulvae is diverse (3). Infection is the most prevalent cause in general practice, predominantly caused by Candida species. Some other specific but non-infectious causes of pruritus vulvae are postmenopausal mucosal atrophy, lichen sclerosus et atrophicus, and psoriasis (4,6). There is, however, a category of patients that suffer from pruritus vulvae without the presence of an infection or other specific causes. This subgroup of vulval complaints has rarely been studied and is therefore the subject of our research (7). A pilot study performed in 25 Dutch general practices registering vulval complaints during 4 weeks showed approximately two new cases of pruritus vulvae without a specific cause per 1000 patients per year (unpublished data). This is in agreement with the aforementioned study in the United Kingdom (1). Women with pruritus vulvae in this Dutch study were predominantly treated with topical steroids. Dutch GPs preferred topical steroids as the treatment of choice. Dutch GPs also mentioned aspects of patient education, such as avoiding cleaning and not using irritative materials as inlays. Nevertheless, the majority prescribed a topical steroid. The effectiveness of topical steroids is mainly studied in trials concerning the treatment of lichen sclerosus Correspondence: A. L. M. Lagro-Janssen, Women s Studies Medicine, Department of General Practice, Radboud University Nijmegen Medical Centre, 117 HAG, PO Box 9101, 6500 HB Nijmegen, the Netherlands. Tel: Fax: a.lagro-janssen@hag.umcn.nl (Received 8 May 2008; accepted 19 December 2008) ISSN print/issn online # 2009 Informa UK Ltd. (Informa Healthcare, Taylor & Francis As) DOI: /
2 30 A. L. M. Lagro-Janssen & S. Sluis (8,9). Application of topical steroids in the vulvar region has long-term side effects, the most important being atrophy of the mucosa (10). Because of these side effects, it is important to establish the benefits of topical steroids compared to less harmful alternatives. The aim of the study was to assess the effectiveness of treatment of non-specific pruritus vulvae with a topical steroid compared to a placebo. Methods The trial was performed in 25 general practices in the Netherlands, of which 13 were located in big cities and 12 in rural areas. The participating GPs were all visited and instructed by the researcher SS. All women between the age of 18 and 55 years presenting with acute as well as recurrent pruritus vulvae were informed about the study and consented to participate (informed consent). Pregnant and breastfeeding women and those who were unable to fill in the questionnaires were excluded. Women were also excluded when the pruritus lasted longer than 4 weeks or was caused by an infection or other specific cause such as postmenopausal atrophy, ulcer, malignancy, psoriasis, atopic dermatitis elsewhere, or lichen sclerosus. A cervical swab was performed to diagnose infections such as Candida albicans, Chlamydia trachomatis, Trichomonas vaginalis,orneisseria gonorrhoeae (8). While waiting for the results, the patient was asked to complete a questionnaire and return after 1 week to discuss the results. No treatment was permitted during this week. During the second appointment, the patient was either excluded (in the case of a positive swab) or included and randomized (in the case of a negative swab). The GP completed a questionnaire, in which the patient s complaints and findings of inspection of the vulvar region were specified. Also, the patient s characteristics such as age, parity, marital status, use of contraceptives, personal-hygiene practices, self-treatment practices, comorbidity, medication, and insurance status (private or state) were collected. Randomization occurred in blocks of four. This was based on the expectation that the participating GPs would include four patients during the study period. All practices received four similar-looking tubes, numbered 1 to 4. Two contained a topical steroid (triamcinolone acetonide 0.1%) and two a placebo cream (cetomacrogol cream, consisting of isopropyl myristate, paraffin, and vaseline). The study was double blind; only one researcher (S.S.) knew which numbers corresponded with the steroid and which with the placebo. The sequence was different for each of the 25 practices. The participating pharmacist made sure that the two ointments were similar in colour, consistency, and smell. The choice of triamcinolone cream was based on a pilot study preceding this trial, which revealed that this class 2 steroid was the GPs treatment of choice for non-specific pruritus vulvae. The patients received a tube with ointment and a checklist diary to score the severity of their itch daily. This diary was also used to monitor user compliance. All patients received a short list of behavioural advice. To measure the severity of itch, we used an 11-point visual analogue scale, with a minimum score of zero ( no itch at all ) and a maximum of 10 ( the worst itch imaginable ). COOP/WONCA charts were used to assess changes in general health before and after treatment (12). This instrument, used by GPs, was designed by the Dartmouth Primary Care Cooperative and WONCA (World Organization of Family Doctors), and comprises seven questions concerning health. In the COOP/WONCA questionnaire, possible answers were numbered from 1 to 5, in which 1 is a good state of function or health and 5 is a poor state of function or health. A questionnaire completed at the beginning of treatment registered patient characteristics and possible contributing factors to vulvar complaints, such as the use of hygienic materials,skin diseases elsewhere, comorbidity, and medication (13). Patients were instructed by their GP to apply the ointment twice a day during 3 weeks and then return for a final consultation. At this stage, GPs were unaware of the kind of treatment the patient had received. GPs collected all registration forms and returned them to the researcher SS. Nine weeks after the end of treatment, patients were contacted by telephone by the research assistant to inquire about the presence of (relapse) complaints. Intention to treat analysis was performed. We defined three outcome measures. First, mean changes in the itch VAS score were measured before and after treatment. Second, we calculated the number of women who were completely cured after treatment (VAS score zero). Change in general health perception measured by the COOP/WONCA charts was the third outcome measure. We used SPSS version for Windows to register all data. Statistical analysis was performed by using the chi-square test (significance pb0.05). The study was approved by the ethics committee of the Radboud University Nijmegen Medical Centre, region Arnhem-Nijmegen (CWOM no ). Results The participating GPs enrolled 81 women presenting with pruritus vulvae (Figure 1). Sixteen patients
3 Effectiveness of topical steroids in pruritus vulvae 31 Patients aged presenting with pruritus vulvae (n = 81) excluded because of infection (n = 16) - Candida (n = 4) - Chlamydia (n = 1) - Streptococcus (n = 1) - Bacterial vaginosis (n = 6) Mixed infection (n = 4) lost before randomization after 1 week (n = 15) - did not show up (n = 3) - cured before treatment (n = 7) - refused participation after 1 week (n = 5) Downloaded By: [Radboud Universiteit Nijmegen] At: 07:15 22 March 2010 one drop out Triamcinolone cream (n = 27) Figure 1. Flow chart of the study population. 50 women randomized n = 26 n = 23 were excluded because an infection was diagnosed, and 15 because, after 1 week, the complaints had subsided or they had refused to participate or did not show up. Fifty patients were randomized: 27 into the triamcinolone group and 23 into the placebo group. There was one drop out because too many data were missing. No significant differences were found between the two groups in patient characteristics such as age, marital status, parity, use of contraceptives, and insurance status (Table I). No differences were found in possible contributing factors to pruritus vulvae such as adverse personal hygiene, self-treatment, and comorbidity (data not shown). The mean severity of itch prior to the intervention was comparable for both groups. Also, compliance, as measured in patient diaries, did not show differences between the two groups. The mean decrease in severity of itch after treatment was 2.08 points for the triamcinolone group and 3.26 points for the placebo group (nonsignificant, p 0.665) (Table II). The percentage of women that reached complete recovery was 42.3% in the triamcinolone group and Placebo (cetomacrogol) (n = 23) 34.8% for the placebo group (non-significant, p0.770). There was no difference in general health perception in the two groups, as measured with the COOP/WONCA charts. Eight patients reported side effects: four in each group. In the triamcinolone group, one patient reported both worsening of existing itch and other side effects, and three patients simply reported other side effects. One patient in the placebo group experienced worsening of the existing itch ; one reported worsening of the itch and other side effects ; and two had other side effects. Side effects described as other consisted of a burning sensation, vaginal discharge, abdominal pain, and low back pain for the placebo group. In the triamcinolone group, pain and a nasty feeling, allergic reaction, burning sensation, and itch around the anus were mentioned as other side effects. The design of our study was double blind. Neither the treated patient nor the treating doctor was aware of the kind of treatment that was used. We checked the blinding after 3 weeks of treatment in both
4 32 A. L. M. Lagro-Janssen & S. Sluis Table I. Patient characteristics of the study population. Triamcinolone group (n26) Placebo group (n23) Mean age, years (SD) 37.8 (11.9) 38.8 (9.3) Marital status Married/living together Living with parents * * Living alone 6 8 Mean parity (SD) 1.35 (1.33) 1.27 (1.35)* Contraceptives 10 9 Oral contraceptives 4 7 Condom 3 1 Hormone, IUD 2 1 Insurance State insurance Private insurance 9 8 Itch level before treatment Mean VAS score (SD) 5.60 (2.06) 6.48 (1.78) * n22; one person did not answer the question. IUD: intrauterine device. No significant differences. patient and doctor questionnaires. All indicated that they were still unaware of the kind of treatment they received (patients) or had given (doctors). After 12 weeks, more than 80% of patients in both groups reported a relapse or continuation of pruritus vulvae. Discussion In this randomized placebo-controlled trial, we investigated the effectiveness of treating non-specific pruritus vulvae with a topical steroid in comparison with a placebo. After 3 weeks of treatment, we found no significant differences. In both groups, there was a reported diminishment of itch after 3 weeks, while less than half of the women completely recovered. In both groups, the relapse rate of vulvar itch after 12 weeks was high (80%). Based on our results, we conclude that treatment of non-specific pruritus vulvae with a topical steroid is not more effective than treatment with a placebo cream. Moreover, both treatments are ineffective in the long run. The reported side effects in both groups were comparable; one out of six patients experienced side effects, such as worsening of the Table II. Effect of treatment: changes in mean itch, as defined by VAS score. Changes in mean itch Triamcinolone group (n26) Placebo group (n23) Mean (SD) 2.08 (2.48) 3.26 (2.80) itch or a burning sensation in the genital region. We expect side effects of topical steroids to increase when used over a longer period of time, especially atrophy (10). Since non-specific pruritus vulvae is likely to be recurrent, women will probably use the ointment for a period much longer than 3 weeks and are therefore at risk of experiencing side effects at a later date. Randomized controlled trials concerning the treatment of pruritus vulvae are rare. We did not find any studies carried out in a general healthcare setting. We therefore believe our study contributes to present knowledge of the treatment of this condition. The size of our study sample does, however, limit our conclusions. Small differences in effectiveness may not have been detected. However, this would raise the question as to what the clinical relevance of these small differences would be. We believe that only distinct differences in effectiveness should influence the choice of treatment and can justify the use of an ointment that has potential long-term side effects. An infection is the most common cause of vulval itch (3). Therefore, a cervical swab was performed preceding the start of treatment. We expected a large number of positive swabs and thus a large number of exclusions, of at least 50% (14). Surprisingly, only 28% of the women presenting with pruritus vulvae were excluded because of a positive swab. Since the participating GPs were well aware of the goal of this study, we presume that they may have pre-selected women that might fit the study design. However, since this remains a matter of assumption, it is hard to estimate the effect of this pre-selection on our results. We expect this phenomenon to have affected our study group as a whole, without causing a bias between the two groups. Women were motivated to take part. We had only one drop out due to missing questionnaires. All women completed the treatment. The randomization was therefore sufficiently adequate. Conclusion Non-specific pruritus vulvae is a harmless but nevertheless annoying complaint which can be shameful and embarrassing. Adverse personal-hygiene practices such as the daily use of panty liners, deodorants, excessive washing of the vulva, or self-medication must be avoided. Triamcinolone cream lacks clear evidence of effectiveness. Therefore, women should no longer be treated with topical steroids as part of standard care. Women should also be informed that vulvar itch is very likely to relapse and that an ordinary cream such as cetomacrogol is the treatment of choice, without long-term side effects.
5 Acknowledgements We would like to thank Frank Martens and Hans Bor for help with statistics. The present study was funded by a grant from the Netherlands Organisation for Health Research and Development (ZonMw) and the Dutch Association of General Practitioners (NHG). Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. References 1. Nunns D, Mandal D. The chronically symptomatic vulva: prevalence in primary health care. Genitourin Med 1996;/72:/ Gates EA, Galask RP. Psychological and sexual functioning in women with vulvae vestibulitis. J Psychosom Obstet Gynaecol 2001;/22:/ Welsh B, Howard A, Cook K. Vulval itch. Aust Fam Physician 2004;/33:/ Fischer GO. The commonest causes of symptomatic vulvar disease: a dermatologist s perspective. Australas J Dermatol 1996;/37:/12. Effectiveness of topical steroids in pruritus vulvae Pincus SH. Vulvar dermatoses and pruritus vulvae. Dermatol clin 1992;/10:/ Foster DC. Vulvar disease. Obstet Gynecol 2002;/100:/ Fischer G, Spurrett B, Fischer A. The chronically symptomatic vulva: aetiology and management. Br J Obstet Gynaecol 1995;/102: / Bracco GL, Carli P. Clinical and histologic effects of topical treatments of vulval lichen sclerosus. A critical evaluation. J Reprod Med 1993;/38:/ Cattaneo A, De Marco A. Clobetasol vs. testosterone in the treatment of lichen sclerosus of the vulvar region. Minerva Ginecol 1992;/44:/ Polano MK. De toepasbaarheid van corticoid zalven en crèmes [The efficacy of topical steroids]. Ned Tijdschrift Geneeskd 1986;/14:/ Ferris DG, Hendrich J, Payne PM, Getts A, Rassekh R, Mathis D, et al. Office laboratory diagnosis of vaginitis. Clinician-performed tests compared with a rapid nucleic acid hybridization test. J Fam Pract 1995;/41:/ van Weel C, König-Zahn C, Touw Otten FWMM, van Duyn NP, Meyboom de Jong B. Measuring functional health status with the COOP/WONCA charts, a manual. Groningen: North Centre for Health Problems; Marin MG, King R, Sfameni S, Dennerstein GJ. Adverse behavioral and sexual factors in chronic vulvar disease. Am J Obstet Genecol 2000;/183:/34.
PARTICIPANT DIARY TREATMENT ALLOCATION: LACTIC ACID GEL
PARTICIPANT DIARY TREATMENT ALLOCATION: LACTIC ACID GEL For site staff completion only: Participating Site: Participant Initials: Participant ID: Date of Randomisation: Allocated Treatment: Lactic Acid
More informationClearance in vulvar lichen sclerosus: a realistic treatment endpoint or a chimera?
DOI: 10.1111/jdv.14516 JEADV SHORT REPORT Clearance in vulvar lichen sclerosus: a realistic treatment endpoint or a chimera? A. Borghi,* A. Virgili, S. Minghetti, G. Toni, M. Corazza Dipartimento di Scienze
More informationPARTICIPANT DIARY TREATMENT ALLOCATION: ORAL METRONIDAZOLE TABLETS
PARTICIPANT DIARY TREATMENT ALLOCATION: ORAL METRONIDAZOLE TABLETS For site staff completion only: Participating Site: Participant Initials: Participant ID: Date of Randomisation: Allocated Treatment:
More informationClincialTrials.gov Identifier: sanofi-aventis. Sponsor/company:
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClincialTrials.gov
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Flutarzole 0,05% w/w cream, Fluticasone propionate
PACKAGE LEAFLET: INFORMATION FOR THE USER Flutarzole 0,05% w/w cream, Fluticasone propionate 1. IDENTIFICATION OF THE MEDICINAL PRODUCT 1.1. Trade name Flutarzole 1.2. Composition Active substance: Fluticasone
More informationWhat are the symptoms of a vulval skin condition?
Information for you Published in December 2013 Skin conditions of the vulva About this information This information is for you if you want to know about skin conditions affecting the vulva. If you are
More informationComparison of Boric Acid with Clotrimazole in the Treatment of Recurrent or Resistant Vulvovaginitis Caused by Non-Albicans Species of Candida
IJMS Vol 33, No 4, December 2008 Original Article Comparison of Boric Acid with Clotrimazole in the Treatment of Recurrent or Resistant Vulvovaginitis Caused by Non-Albicans Species of Candida N. Khadem,
More informationKelly H. Tyler, MD, FACOG, FAAD S052 Gender Dermatology: Diagnosis and Treatment of Genital Skin Disorders Vulvar Dermatitis
Vulvar Dermatitis Kelly H. Tyler, MD, FACOG, FAAD Assistant Professor The Ohio State University Department of Internal Medicine, Division of Dermatology Department of Obstetrics and Gynecology Center for
More informationTrichomoniasis allergic flagyl
Trichomoniasis allergic flagyl The Borg System is 100 % Trichomoniasis allergic flagyl Dec 1, 2004. Because metronidazole is the only agent that is used to treat T. vaginalis infection, potential management
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationConflicts of interest
Vulvar Cases 2 nd PANHELLANIC CONGRESS on Lower Genital Tract Disorders December 14-16 Grand Hyatt Athens Lynette J. Margesson MD FRCPC Assistant Professor of Obstetrics & Gynecology and Surgery(Dermatology)
More informationDon t gamble. with your SEXUAL. health WHY A CHECK UP IS IMPORTANT
Don t gamble with your SEXUAL health WHY A CHECK UP IS IMPORTANT Introduction Most infections caught through having sex can be treated easily and painlessly. If you are worried that you have put yourself
More informationSTI Diagnostics Redesign. HVS and Chlamydia Resource Pack
Important! 1. This information is intended to support practitioners in the management of common sexual health problems and it is therefore essential that each doctor and nurse receives a copy. 2. Future
More informationBACTERIAL VAGINOSIS. Patient Information Leaflet. Your Health. Our Priority. Microbiology Pathology Department.
BACTERIAL VAGINOSIS Patient Information Leaflet Your Health. Our Priority. Page 2 of 5 Bacterial vaginosis What causes bacterial vaginosis? The cause of bacterial vaginosis sometimes called BV is not really
More informationInvestigation and Management of Vaginal Discharge in Adult Women
Investigation and Management of Vaginal Discharge in Adult Women SUMMARY POINTS A detailed history, including sexual history, should be taken to explore potential causes and guide investigation and management.
More informationAddress: 1. What is your vulvar diagnosis (if known)? 2. What is the main symptom for which you are coming to the Vulvar Mucosal Specialty Clinic?
Referring Physician Address: Phone: Fax: Requirements before your appointment: All records from previous physicians participating in your current condition must be received by the time of your appointment.
More informationWhat s New. Vaginal Discharge Protocol. History
What s New Information has been added on interpreting vaginal scoring system and AV scores. Vaginal Discharge Protocol History Low risk STI PLUS Typical BV or VVC history AND No symptoms of PID High risk
More informationVaginal involvement in genital erosive lichen planus
Acta Obstetricia et Gynecologica. 2010; 89: 966 970 SHORT REPORT Vaginal involvement in genital erosive lichen planus ANNE LISE ORDING HELGESEN 1,2,3, PETTER GJERSVIK 3,4, PETER JEBSEN 5, ROLF KIRSCHNER
More informationVulval dermatoses. Dr Fiona Lewis, Consultant Dermatologist St John s Institute of Dermatology, London & Heatherwood & Wexham Park Hospital, Slough
Vulval dermatoses Dr Fiona Lewis, Consultant Dermatologist St John s Institute of Dermatology, London & Heatherwood & Wexham Park Hospital, Slough Pigmentation Vulvodynia Ulcers Genetic Pruritus VULVAL
More informationProcessing of female genital specimens at Labtests and Northland Pathology Laboratory
Consultation document Processing of female genital specimens at Labtests and Northland Pathology Laboratory Author: Dr Arlo Upton Page 1 of 9 Date: 07/03/16 Table of contents 1. INTRODUCTION...3 2. CURRENT
More informationSexually Transmitted Diseases. Tr ichomonas. infection. Questions & Answers
Sexually Transmitted Diseases Tr ichomonas infection Questions & Answers What is trichomonas infection or trichomoniasis? This is a common sexually transmitted genital infection caused by the parasite
More informationPackage leaflet: Information for the user. Fluticrem 0.05% cream Fluticasone propionate
Package leaflet: Information for the user Fluticrem 0.05% cream Fluticasone propionate Read all of this leaflet carefully before you start using this medicine because it contains important information
More informationOCCG SERVICE SPECIFICATION (2017/18)
OCCG SERVICE SPECIFICATION (2017/18) Primary Care Service for Skin Cancers: Dermatology Shared Care Monitoring for Melanoma, Lichen Sclerosus and Squamos Cell Carcinoma 1. Background For patients who have
More informationLichen sclerosus. Lichen planus
Lichen sclerosus Lichen planus Dr Fiona Lewis, Consultant Dermatologist, Heatherwood and Wexham Park NHS Foundation Trust & St John s Institute of Dermatology, GSTT Outline Typical features of lichen sclerosus
More informationLichen Sclerosus. Exceptional healthcare, personally delivered
Lichen Sclerosus Exceptional healthcare, personally delivered Lichen Sclerosus (LS) is an itchy skin condition usually affecting genital skin, but it can occur elsewhere. It affects women more often than
More informationSexually Transmissible Infections (STI) and Blood-borne Viruses (BBV) A guide for health promotion workers
Sexually Transmissible Infections (STI) and Blood-borne Viruses (BBV) A guide for health promotion workers Sexual & Reproductive Health Western Australia Chlamydia (bacterial infection) Unprotected vaginal
More informationJMSCR Vol 05 Issue 04 Page April 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i4.70 Effectiveness of Hygiene Intervention
More information** IMPORTANT!! PLEASE READ THIS BEFORE YOU FILL OUT YOUR QUESTIONNAIRE! **
** IMPORTANT!! PLEASE READ THIS BEFORE YOU FILL OUT YOUR QUESTIONNAIRE! ** WHY AM I FILLING OUT THIS FORM? Your responses will help us to understand your experience. Please take your time and try to answer
More information2
1 2 3 1. Usinger KM et al. Intrauterine contraception continuation in adolescents and young women: a systematic review. J Pediatr Adolesc Gynecol 2016; 29: 659 67. 2. Kost K et al. Estimates of contraceptive
More informationLichen planus. Information for patients Gynaecology
Lichen planus Information for patients Gynaecology page 2 of 8 What is lichen planus? Lichen planus is a non-cancerous, inflammatory skin condition that causes an itchy, non-infectious rash (small purple
More informationOBSTETRICS & GYNECOLOGY
JANUARY 2012 COMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING WWW.CPSRXS. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Female Sexual Arousal
More informationVulvodynia / Pain. NVA RESEARCH UPDATE NEWSLETTER September 2005
NVA RESEARCH UPDATE NEWSLETTER September 2005 www.nva.org This newsletter has been supported, in part, through a grant from the Enterprise Rent-A-Car Foundation. www.enterprise.com This newsletter is quarterly
More informationVulvodynia and vestibulectomy
Vulvodynia and vestibulectomy treatment of an important problem for a gynecologist Dr. Tolga Taşçı Associate Proffessor of Obstetrics and Gynecology Gynecologic Oncologist Okmeydanı Teaching and Research
More informationPatient Satisfaction of Surgical Treatment of Clitoral Phimosis and Labial Adhesions Caused by Lichen Sclerosus
ORIGINAL RESEARCH WOMEN S SEXUAL HEALTH Patient Satisfaction of Surgical Treatment of Clitoral Phimosis and Labial Adhesions Caused by Lichen Sclerosus Anne N. Flynn, MD,* Michelle King, MSc, Mollie Rieff,
More informationA population-based assessment of chronic unexplained vulvar pain: have we underestimated the prevalence of vulvodynia?
NVA RESEARCH UPDATE NEWSLETTER Volume III, Issue II June 2003 www.nva.org This newsletter has been supported, in part, through an unrestricted educational grant from Personal Products Company, a division
More information4/3/2017 DIAGNOSIS AND THERAPY OF RECURRENT VULVOVAGINAL SYMPTOMS BACTERIAL VAGINOSIS EPIDEMIOLOGY OBJECTIVES
DIAGNOSIS AND THERAPY OF RECURRENT VULVOVAGINAL SYMPTOMS KELLY HODGES, MD (NO DISCLOSURES) OBJECTIVES REVIEW THE TWO MOST COMMON CAUSES OF RECURRENT ABNORMAL DISCHARGE (CANDIDA AND BV) REVIEW THE MOST
More informationScream Cream. Ingredients: Aminophylline 15-mg, Ergoloid mesylate 0.25-mg, Pentoxifylline 25-mg and L-Arginine 30-mg
At LifeCare Pharmacy we understand that women have different needs at different stages of their lives. Maintaining a healthy and balanced lifestyle can be a difficult struggle. The chronic stress of overly
More informationCommunity Gynaecology. Top Tips for GPs
Community Gynaecology Top Tips for GPs Top Tips for GPs Case Scenarios- common referral themes 6 topics What you can do in Primary Care to avoid or before referral. What we don t need to see Triage ensures
More informationLichen sclerosus (LS) is an uncommon inflammatory. Constipation as a Feature of Anogenital Lichen Sclerosus in Children
Mandi L. Maronn, MD*, and Nancy B. Esterly, MD ABSTRACT. Objective. To call attention to constipation as a frequent sign of lichen sclerosus (LS) in girls. Methods. A focused questionnaire was sent to
More informationThe comparison or control group may be allocated a placebo intervention, an alternative real intervention or no intervention at all.
1. RANDOMISED CONTROLLED TRIALS (Treatment studies) (Relevant JAMA User s Guides, Numbers IIA & B: references (3,4) Introduction: The most valid study design for assessing the effectiveness (both the benefits
More informationVaginitis. Antibiotics Changes in hormone levels due to pregnancy, breastfeeding, or menopause Douching Spermicides Sexual intercourse Infection
WOMENCARE A Healthy Woman is a Powerful Woman (407) 898-1500 Vaginitis Vaginitis is an inflammation of a woman s vagina. It is one of the most common reasons why women see their health care providers.
More informationVaginitis. Is vaginal discharge ever normal? Women with vaginal discharge. Vaginal symptoms are very common. Patient with chronic vaginal discharge
Vaginitis Is the wet prep out of the building? No disclosures related to this topic Images are cited with permissions Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Health
More informationComplex Vaginitis Cases: Applying New Diagnostic Methods to Enhance Patient Outcomes ReachMD Page 1 of 5
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationPrescriber and Pharmacy Guide for the Tracleer REMS Program
Prescriber and Pharmacy Guide for the Tracleer REMS Program Please see accompanying full Prescribing Information, including BOXED WARNING for hepatotoxicity and teratogenicity. Introduction to Tracleer
More informationDifferentiation between women with vulvovaginal symptoms who are positive or negative for Candida species by culture
Infect Dis Obstet Gynecol 2001;9:221 225 Differentiation between women with vulvovaginal symptoms who are positive or negative for species by culture Iara M. Linhares 1,2, Steven S. Witkin 2, Shirlei D.
More informationHerpes What is it? How is it transmitted? How is it treated?
Herpes What is it? How is it transmitted? How is it treated? A service provided by page 2 of 12 What is genital herpes? Genital herpes is caused by the herpes simplex virus (HSV). It is a very common virus.
More informationHelping stop the spread of sexually transmitted infections
Issue Eight Helping stop the spread of sexually transmitted infections This month: Sexual health Get clued up on sexual health with issue eight of Your Wellbeing, where we talk about the symptoms, myths
More informationCANDIDIASIS (WOMEN) Single Episode. Clinical Features. Diagnosis. Management
CANDIDIASIS (WOMEN) What s new: Section on Management of Vulvovaginal Non-Albicans Candida Infection in Adults approved by GGC antimicrobial team Routine candida sensitivity testing has been discontinued,
More informationWe customize individual prescriptions for the specific needs of our patients.
We customize individual prescriptions for the specific needs of our patients. J A N U A R Y 2 0 1 3 I N S I D E T H I S I S S U E : Vulvodynia 2 Vulvovaginal Candidiasis Breastfeeding Challenges 3 4 P
More informationA Randomized, Double-Blind, Placebo-Controlled Trial of 5-Fluorouracil for the Treatment of Cervicovaginal Human Papillomavirus
Infectious Diseases in Obstetrics and Gynecology 7:186-189 (1999) (C) 1999 Wiley-Liss, Inc. A Randomized, Double-Blind, Placebo-Controlled Trial of 5-Fluorouracil for the Treatment of Cervicovaginal Human
More informationWhat you need to know about EGW
For the treatment of external genital and perianal warts (EGW) What you need to know about EGW Indication VEREGEN is indicated for the topical treatment of external genital and perianal warts (Condylomata
More informationContraception and Kidney Problems: Advice for Young Adults
Contraception and Kidney Problems: Advice for Young Adults Delivering the best in care UHB is a no smoking Trust To see all of our current patient information leaflets please visit www.uhb.nhs.uk/patient-information-leaflets.htm
More informationSexually Transmitted Diseases. Chlamydial. infection. Questions and Answers
Sexually Transmitted Diseases Chlamydial infection Questions and Answers What is chlamydial infection? It is a sexually transmitted infection caused by the bacteria Chlamydia trachomatis, being one of
More informationSexual health: Hot topics. Anne Connolly Vice President FSRH
Sexual health: Hot topics Anne Connolly Vice President FSRH To cover Contraception choices Contraception safety Sexual history taking Relevant tests We don t do great. 30 50% pregnancies are unplanned
More informationVIN/VAIN O C T O B E R 3 RD J M O R G A N
VIN/VAIN O C T O B E R 3 RD 2 0 1 8 J M O R G A N Vaginal Intraepithelial Neoplasia VAIN I, II, III Incidence 0.1/100,000 women in US Mean age 50s (J Womens Health (Larchmt) 2009:18:1731) (J Obstet Gynaecol
More informationA Guide to. Bacterial Vaginosis. Training Guide
A Guide to Bacterial Vaginosis Training Guide Bacterial Vaginosis What is Bacterial Vaginosis (BV)? The normal vaginal flora contains anaerobic and aerobic bacteria, dominated by the Lactobacillus species
More informationNon-gonococcal urethritis. Looking after your sexual health
Non-gonococcal urethritis Looking after your sexual health 2 3 Non-gonococcal urethritis Urethritis is inflammation (pain, redness or soreness) of the urethra (the tube that carries urine out of the body).
More informationAnne Arundel Medical Center Informed Consent
Informed Consent Title: Exploratory Trial of Autologous Platelet Rich Plasma (PRP) Intradermal Injections for the Treatment of Vulvar Lichen Sclerosus Investigator: Andrew Goldstein, M.D. Telephone Study
More informationDisclosures Dr. Lynette Margesson
Management of Vulvar Pruritus 2 nd PANHELLANIC CONGRESS on Lower Genital Tract Disorders December 14-16 Grand Hyatt Athens Lynette J. Margesson MD FRCPC Assistant Professor of Obstetrics & Gynecology and
More informationSexually Transmitted Infections in the Adolescent Population. Abraham Lichtmacher MD FACOG Chief of Women s Services Lovelace Health System
Sexually Transmitted Infections in the Adolescent Population Abraham Lichtmacher MD FACOG Chief of Women s Services Lovelace Health System STI in the Adolescent High school students nationwide, 34.2% were
More informationWhat You Need to Know. Sexually Transmitted Infections (STIs)
What You Need to Know Sexually Transmitted Infections (STIs) What You Need to Know About STIs What are STIs? Sexually transmitted infections (STIs) are diseases that spread through sexual contact. If you
More informationKeywords Health-related quality of life, EQ-5D, cross-sectional study, Chlamydia trachomatis, women s health
Original research article Health-related quality of life and Chlamydia trachomatis infection in sexually experienced female inner-city students: a community-based cross-sectional study International Journal
More informationLichen sclerosus. Information for patients Gynaecology
Lichen sclerosus Information for patients Gynaecology page 2 of 8 What is lichen sclerosus? Lichen sclerosus is a skin condition that most often affects the vulva (the outer folds of skin around your vagina).
More informationDisorders of the vulva
Vulval lesions Disorders of the vulva Terminology standardised by the International Society for the Study of Vulvovaginal Disease(ISSVD) Classification 1.Nonneoplastic epithelial disorders of vulva Lichen
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Psoriasis (excluding widespread plaque psoriasis) Psoriasis is a common chronic skin disorder. Estimates of the prevalence (proportion
More informationWHITE PAPER SmartXide 2 V 2 LR. MonaLisa Touch Dual Probe Therapy for the Treatment of Lichen Sclerosus and Vaginal Atrophy
WHITE PAPER SmartXide 2 V 2 LR MonaLisa Touch Dual Probe Therapy for the Treatment of Lichen Sclerosus and Vaginal Atrophy DEKA White Paper SMARTXIDE 2 V 2 LR November 2015 MonaLisa Touch Dual Probe Therapy
More informationIcd 10 code for vaginal itching and burning
P ford residence southampton, ny Icd 10 code for vaginal itching and burning 10-3-2018 Learn how we use endoscopic procedures, minimal access surgery, interventional radiology, & radiation oncology services
More informationWhat's the problem? - click where appropriate.
STI Tool v 1.9 @ 16/11/2017 What's the problem? - click where appropriate. Male problems: screening urethral symptoms proctitis in gay men lumps or swellings ulcers or sores skin rash and/or itch Female
More informationSexual Health Services (Emergency Hormonal Contraception, Chlamydia Screening, Condom Distribution & Pregnancy Testing) in Pharmacies.
Local Enhanced Service (LES) Specification for: Sexual Health Services (Emergency Hormonal Contraception, Chlamydia Screening, Condom Distribution & Pregnancy Testing) in Pharmacies. 1. Introduction 2.
More informationMANAGEMENT OF ACUTE PELVIC INFLAMMATORY DISEASE
WOMEN AND NEWBORN HEALTH SERVICE CLINICAL GUIDELINES SECTION C: GUIDELINES RELEVANT TO GYNAECOLOGY 6.1 ABDOMINAL / PELVIC PAIN 6.1 ACUTE PAIN Authorised by: OGCCU 6.1.3 TREATMENT 6.1.3.1 MANAGEMENT OF
More informationThe Balanced Counseling Strategy Plus: A Toolkit for Family Planning Service Providers Working in High STI/HIV Prevalence Settings.
The Balanced Counseling Strategy Plus: A Toolkit for Family Planning Service Providers Working in High STI/HIV Prevalence Settings Counseling Cards Checklist to be reasonably sure a woman is not pregnant
More informationSmear Takers Talk- Problems you may encounter during smear taking and things to consider.
Smear Takers Talk- Problems you may encounter during smear taking and things to consider. Aims and Objectives Raise awareness Identify concerns Manage them STIs Menopausal symptoms Psycho-sexual problems
More informationBD Affirm VPIII Microbial Identification Test
BD Affirm VPIII Microbial Identification Test VAGINAL INFECTIONS: The power of DNA technology for better patient care Diagnose and treat vaginitis/vaginosis patients correctly the first time Vaginitis
More informationBD Affirm VPIII Microbial Identification Test VAGINAL INFECTIONS:
BD Affirm VPIII Microbial Identification Test VAGINAL INFECTIONS: The power of DNA technology for better patient care Accurate test results on three pathogens with DNA technology The BD Affirm VPIII Microbial
More informationPatient Leaflet : Information for the user Locoid Cream 0.1% w/w Hydrocortisone butyrate
Patient Leaflet : Information for the user Locoid Cream 0.1% w/w Hydrocortisone butyrate Read all of this leaflet carefully before you start using this medicine because it contains important information
More informationA Prospective Study Of Comparison Of Efficacy Of Two Combination Treatment Regimens In Syndromic Treatment Of Pelvic Inflammatory Disease
ISPUB.COM The Internet Journal of Gynecology and Obstetrics Volume 5 Number 2 A Prospective Study Of Comparison Of Efficacy Of Two Combination Treatment Regimens In Syndromic Treatment Of Pelvic Inflammatory
More informationPostmenopausal Vulvar Pruritus - Colposcopic Diagnosis and Treatment
Postmenopausal Vulvar Pruritus - Colposcopic Diagnosis and Treatment Pages with reference to book, From 315 To 317 A Bilge Sener, Neslihan C. Seckin, Oya Gokmen ( Departments of Menopause, Dr. Z.T.B. Women
More informationSTIs in Primary Care. Dr Eleanor Draeger 19 th January 2016
STIs in Primary Care Dr Eleanor Draeger 19 th January 2016 Poli=cs! 2012! Health and Social Care act! Sexual Health commissioning moved to local authority! 2015! 200 million cuts to public health! 40%
More informationCanesten Clotrimazole Thrush Treatment Once Cream
Canesten Clotrimazole Thrush Treatment Once Cream Clotrimazole vaginal cream 100 mg/g What is in this leaflet This leaflet answers some common questions about Canesten Thrush Treatment. It does not contain
More informationLEARNING NATIONAL CURRICULUM. Herpes virus. This section aims to teach students how sexual activity can lead to the spread of microbes and disease.
This section aims to teach students how sexual activity can lead to the spread of microbes and disease. Section 2.3, Sexually Transmitted Infections, teaches students how easily potentially harmful microbes
More informationSTIs: Practical Aspects of Management
STIs: Practical Aspects of Management Dr Heather Young FAChSHM DipPH Christchurch Sexual Health heathery@xtra.co.nz 027 343 4963 Sexually Transmitted Infections BACTERIAL STIs: CHLAMYDIA GONORRHOEA SYPHILIS
More informationAldo Campana Training Course in Reproductive Health/ Sexual Health Research Geneva 2006
Female dyspareunia Aldo Campana Training Course in Reproductive Health/ Sexual Health Research Geneva 2006 Female dyspareunia Terms and definitions Prevalence Etiology Evaluation and differential diagnosis
More informationBurdensome Vaginal Infections: Best Diagnostic Practices for Driving Better Patient Outcomes
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationPATIENT INFORMATION LEAFLET
KLOBATE 0.05% cream For topical use. PATIENT INFORMATION LEAFLET Active substance(s): 0.05% clobetasol contains 17-propionate. Excipient(s): Stearyl alcohol, propylene glycol, vaseline, sorbitan sesquioleate,
More informationUSER GUIDE FOR SPECIMEN COLLECTION
DIAGNOSTIC LAB SPECIMEN COLLECTION GUIDE USER GUIDE FOR SPECIMEN COLLECTION ACM GLOBAL LABORATORIES DIAGNOSTIC SERVICES ACM Global Laboratories offers a comprehensive menu of services that support many
More informationSEXUAL RELATIONSHIPS AND FERTILITY FOLLOWING SPINAL CORD INJURY
NATIONAL SPINAL INJURIES CENTRE STOKE MANDEVILLE HOSPITAL A HANDOUT PREPARED FOR PATIENTS BY SPINAL OUTPATIENT SERVICES SEXUAL RELATIONSHIPS AND FERTILITY FOLLOWING SPINAL CORD INJURY Mary Leonard, RGN.
More informationAPPENDIX A SERVICE SPECIFICATION
Service Specification No. Service Authority Lead Provider Lead 2013/14 APPENDIX A SERVICE SPECIFICATION Participation in the Ruclear chlamydia and gonorrhoea screening programme (General practices) Period
More informationHow is it transferred?
STI s What is a STI? It is a contagious infection that is transferred from one person to another through sexual intercourse or other sexually- related behaviors. How is it transferred? The organisms live
More informationDiagnosis and Treatment of Respiratory Illness in Children and Adults
Page 1 of 9 Main Algorithm Annotations 1. Patient Reports Some Combination of Symptoms Patients may present for an appointment, call into a provider to schedule an appointment or nurse line presenting
More informationAn updated User Survey Of LadyBalance Vaginal Tablets
An updated User Survey Of LadyBalance Vaginal Tablets By M.Sci. Inge Dorthe Hansen February 2018 Contents Update of user survey... 3 Collection of Data... 3 The Use of LadyBalance... 3 Effects of LadyBalance...
More informationInnovations in the Management of Dyspareunia
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationThe Vulvar Lichen Disorders: Simplex, Sclerosus, Planus
The Vulvar Lichen Disorders: Simplex, Sclerosus, Planus Paul Summers, M.D. Department of Obstetrics and Gynecology University of Utah School of Medicine Areas of Concern 1. Dermatopathology 2. Spongiotic
More informationDOWNLOAD OR READ : BACTERIAL VAGINOSIS PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : BACTERIAL VAGINOSIS PDF EBOOK EPUB MOBI Page 1 Page 2 bacterial vaginosis bacterial vaginosis pdf bacterial vaginosis Bacterial vaginosis (BV) is a condition that happens when there
More informationVulval intraepithelial neoplasia. Information for patients Gynaecology
Vulval intraepithelial neoplasia Information for patients Gynaecology page 2 of 8 What is vulval intraepithelial neoplasia? Vulval intraepithelial neoplasia (VIN) is not cancer. VIN is a disease of the
More informationSelf-Diagnosed Sensitive Skin in Women with Clinically Diagnosed Atopic Dermatitis
ORIGINAL RESEARCH SPECIAL ISSUE Self-Diagnosed Sensitive Skin in Women with Clinically Diagnosed Atopic Dermatitis Miranda A. Farage 1, Philip Bowtell 2, and Alexandra Katsarou 3 1 Feminine Clinical Sciences,
More information1g cream or ointment contains 1 mg methylprednisolone aceponate.
CONSUMER MEDICINE INFORMATION ADVANTAN 1g cream or ointment contains 1 mg methylprednisolone aceponate. What is in this leaflet Please read this leaflet carefully before you start using ADVANTAN. It will
More informationManagement of benign vulval dermatoses in primary care
PRESCRIBING IN PRACTICE Management of benign vulval dermatoses in primary care MITESH PATEL AND DAVID NUNNS SPL Vulval dermatoses can be difficult to manage in primary care, and GPs need to be aware of
More informationSTI Review. CALM: STI/HIV - Lesson One (Handout 3) Bacteria/ Transmission. Symptoms. Disease. Virus
STI Review Bacteria/ Virus? Transmission Chlamydia Bacteria Unprotected vaginal or anal sex with a person who has Chlamydia Genital Herpes Virus By direct contact with the sores or blisters of an infected
More informationVestibulodynia Terminology Clinical features of the disease Ethiopatogenesis Treatment Multidisciplinary vulvar clinic Vestibulectomy
From Pain to Pleasure Surgical Treatment of Vestibulodynia Päivi Tommola Specialist in Gynecology 13.10.2010 GKS Vestibulodynia Terminology Clinical features of the disease Ethiopatogenesis Treatment Multidisciplinary
More information